AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2022

Jun 24, 2022

30604_dirs_2022-06-24_febc7d17-40c3-4b42-9385-f62dcd2c591a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2022-06-22

Reporting Person: Cook Jennifer E. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-22	Stock Option (right to buy)	$8.45	A	104921	Acquired	2032-06-22	Common Stock (104921)	Direct

Footnotes

F1: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.